Answers are grounded in this paper and cite their sources.
Lung cancer (LC) is the leading cause of cancer-related death worldwide. Its overall poor prognosis is attributable to the fact that most patients remain asymptomatic until the disease is advanced and, therefore, present with late-stage incurable disease. e rationale for LC screening is that early detection of asymptomatic disease oers the opportunity for earlier intervention, at a stage when denitive cure is still feasible, which has the potential to reduce LC-related mortality and morbidity. e ndings of the National Lung Screening Trial provided the rst strong evidence in support of this rationale. Since its publication, several professional organisations and societies have developed guidelines recommending the implementation of LC screening with low-dose computed tomography in asymptomatic, high-risk individuals. Although the benets of such screening programmes may be signicant, they must be carefully weighed against the potential harms to the relatively large number of healthy individuals who would undergo screening. is review examines the available evidence and current recommendations for LC screening, including benets, potentials harms and requirements for implementation of a high-quality, safe and eective programme. In addition, the costs and availability of LC screening programmes in both the global and local settings are considered.
No takes yet. Share an insight, caveat, or question.
Bronwyn Schar (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: